These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31430345)

  • 1. An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer.
    Pujol JL; Coffy A; Camerini A; Kotsakis A; Mencoboni M; Gusella M; Pasini F; Pezzuto A; Banna GL; Bilir C; Samantas E; Barlesi F; Roch B; Guillou A; Daurès JP
    PLoS One; 2019; 14(8):e0220988. PubMed ID: 31430345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and toxicity of metronomic oral vinorelbine monotherapy in patients with non-small cell lung cancer: a meta-analysis.
    Xu K; Liu T; Zhang J; Zhou Y; Yang F; Ren T
    Int J Clin Oncol; 2020 Sep; 25(9):1624-1634. PubMed ID: 32472208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer: a multicenter international retrospective analysis.
    Camerini A; Banna GL; Cinieri S; Pezzuto A; Mencoboni M; Rosetti F; Figueiredo A; Rizzo P; Ricci A; Langenhoven L; Santo A; Addeo A; Amoroso D; Barata F
    Clin Transl Oncol; 2019 Jun; 21(6):790-795. PubMed ID: 30448956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms.
    Gusella M; Pasini F; Caruso D; Barile C; Modena Y; Fraccon AP; Bertolaso L; Menon D; Crepaldi G; Bononi A; Spezzano R; Telatin GA; Corona G; Padrini R
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):493-500. PubMed ID: 30542768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metronomic Oral Vinorelbine: An Alternative Schedule in Elderly and Patients PS2 With Local/Advanced and Metastatic NSCLC Not Oncogene-addicted.
    Rossi D; Lippe P; Rocchi MBL; Sarti D; Catalano V; Graziano F; Giordani P; Baldelli A; Fedeli SL; Imperatori L; Laici G; Cappelletti C; Tamburrano T; Bracci R; Alessandroni P
    In Vivo; 2020; 34(5):2687-2691. PubMed ID: 32871800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of First-line Chemotherapy with Metronomic Single-agent Oral Vinorelbine in Elderly Patients with NSCLC.
    Mencoboni M; Filiberti RA; Taveggia P; Del Corso L; Del Conte A; Covesnon MG; Puccetti C; Donati S; Auriati L; Amoroso D; Camerini A
    Anticancer Res; 2017 Jun; 37(6):3189-3194. PubMed ID: 28551663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study.
    Briasoulis E; Aravantinos G; Kouvatseas G; Pappas P; Biziota E; Sainis I; Makatsoris T; Varthalitis I; Xanthakis I; Vassias A; Klouvas G; Boukovinas I; Fountzilas G; Syrigos KN; Kalofonos H; Samantas E
    BMC Cancer; 2013 May; 13():263. PubMed ID: 23718900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group.
    Kontopodis E; Hatzidaki D; Varthalitis I; Kentepozidis N; Giassas S; Pantazopoulos N; Vardakis N; Rovithi M; Georgoulias V; Agelaki S
    J Chemother; 2013 Feb; 25(1):49-55. PubMed ID: 23433445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metronomic Chemotherapy with Vinorelbine Produces Clinical Benefit and Low Toxicity in Frail Elderly Patients Affected by Advanced Non-Small Cell Lung Cancer.
    D'Ascanio M; Pezzuto A; Fiorentino C; Sposato B; Bruno P; Grieco A; Mancini R; Ricci A
    Biomed Res Int; 2018; 2018():6278403. PubMed ID: 30225260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy.
    Banna GL; Camerini A; Bronte G; Anile G; Addeo A; Rundo F; Zanghì G; Lal R; Libra M
    Anticancer Res; 2018 Jun; 38(6):3689-3697. PubMed ID: 29848729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of single-agent oral vinorelbine in elderly (> or =70 years) patients with advanced non-small-cell lung cancer and poor performance status.
    Camerini A; Valsuani C; Mazzoni F; Siclari O; Puccetti C; Donati S; Rondini M; Tartarelli G; Puccinelli P; Di Costanzo F; Amoroso D
    Ann Oncol; 2010 Jun; 21(6):1290-1295. PubMed ID: 19914959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial).
    Camerini A; Puccetti C; Donati S; Valsuani C; Petrella MC; Tartarelli G; Puccinelli P; Amoroso D
    BMC Cancer; 2015 May; 15():359. PubMed ID: 25943747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial.
    Platania M; Pasini F; Porcu L; Boeri M; Verderame F; Modena Y; Del Conte A; Nichetti F; Garassino MC; Martinetti A; Sottotetti E; Cavanna L; Vattemi E; Pozzessere D; Bertolini A; Irtelli L; Verri C; Sozzi G; Proto C; Pastorino U; Torri V; Fraccon AP; Spinnato F; Signorelli D; Lo Russo G; Tuzi A; Gallucci R; Cinieri S; Mencoboni M; Antonelli P; Giacomelli L; de Braud F
    Lung Cancer; 2019 Jun; 132():17-23. PubMed ID: 31097088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
    Yue D; Xu S; Wang Q; Li X; Shen Y; Zhao H; Chen C; Mao W; Liu W; Liu J; Zhang L; Ma H; Li Q; Yang Y; Liu Y; Chen H; Wang C
    Lancet Respir Med; 2018 Nov; 6(11):863-873. PubMed ID: 30150014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a phase II trial of efficacy and toxicity.
    Kanard A; Jatoi A; Castillo R; Geyer S; Schulz TK; Fitch TR; Rowland KM; Nair S; Krook JE; Kugler JW
    Lung Cancer; 2004 Mar; 43(3):345-53. PubMed ID: 15165094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer.
    Clark JI; Kancharla K; Qamar R; Fisher S; Hantel A; Panganiban J; Millbrandt L; Albain KS
    Lung Cancer; 2001 Nov; 34(2):271-7. PubMed ID: 11679186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].
    Bartsch V
    Onkologie; 2006 Mar; 29 Suppl 1():1-28. PubMed ID: 16534241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy and Toxicity of Metronomic Oral Vinorelbinen in Advanced Non-small Cell Lung Cancer after Failure to Multiple-lines Treatments].
    Yao S; Gu Y; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):737-740. PubMed ID: 29167002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients.
    Barlesi F; Imbs DC; Tomasini P; Greillier L; Galloux M; Testot-Ferry A; Garcia M; Elharrar X; Pelletier A; André N; Mascaux C; Lacarelle B; Cheikh RE; Serre R; Ciccolini J; Barbolosi D
    Oncotarget; 2017 Jul; 8(29):47161-47166. PubMed ID: 28525370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral Metronomic Vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer: outcome and pharmacokinetics in the real world.
    Pasini F; Barile C; Caruso D; Modena Y; Fraccon AP; Bertolaso L; Menon D; La Russa F; Crepaldi G; Bononi A; Spezzano R; Padrini R; Corona G; Gusella M
    Invest New Drugs; 2018 Oct; 36(5):927-932. PubMed ID: 29956056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.